<DOC>
	<DOC>NCT01427712</DOC>
	<brief_summary>This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients due to cystic fibrosis receiving the treatment with LipaCreon in order to evaluate the effective and safe use of LipaCreon.</brief_summary>
	<brief_title>Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Pancreatic Diseases</mesh_term>
	<criteria>Inclusion Criteria Patients who receive LipaCreon for the replacement of pancreatic digestive enzymes in pancreatic exocrine insufficiency due to cystic fibrosis Exclusion Criteria Patients with a history of hypersensitivity to the ingredient of LipaCreon. Patients with a history of hypersensitivity to porcine protein</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Gastrointestinal Agents</keyword>
	<keyword>Pancreatic Diseases</keyword>
	<keyword>Pancrelipase</keyword>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
</DOC>